
    
      This is an open label, single arm, and Phase II study of the combination of Letrozole and
      Bevacizumab in patients with newly diagnosed breast cancer. Patients meeting the eligibility
      criteria and who have signed the consent form will start Letrozole 2.5 mg by mouth a day and
      Bevacizumab 15 mg per Kg IV every 3 weeks for 18 weeks (24 weeks if still responding at week
      18 if approved by the PI). After neoadjuvant therapy, participants will undergo surgical
      treatment and will receive adjuvant therapy according to the treating physician.
    
  